Literature DB >> 758243

Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose or warfarin.

J T Slattery, G Levy, A Jain, F G McMahon.   

Abstract

The purpose of this investigation was to determine the effect of the nonsteroidal anti-inflammatory drug naproxen on the elimination kinetics and anticoagulant activity of warfarin. Ten healthy men received one oral dose of 50 mg racemic warfarin alone and with naproxen, 375 mg twice daily for 17 days beginning 10 days before warfarin. Naproxen administration caused a small but statistically significant increase in the free fraction of warfarin in serum but had no significant effect on the total clearance, volume of distribution, half-life, and anticoagulant activity of warfarin. Warfarin, on the other hand, apparently enhances the serum protein binding of haproxen. There was substantial intersubject variation but very little intrasubject variation in the anticoagulant effect of warfarin. The intersubject variation of the anticoagulant effect was not related to the elimination kinetics of warfarin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 758243     DOI: 10.1002/cpt197925151

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics.

Authors:  B Whiting; R L Williams; M Lorenzi; J C Varady; D S Robins
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 5.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

6.  In vivo plasma protein binding interaction between valproic acid and naproxen.

Authors:  R Grimaldi; S Lecchini; F Crema; E Perucca
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

Review 7.  Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

Review 8.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

Review 10.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.